Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Oklahoma takes on drugmakers J&J, Teva in landmark opioid trial

Published 05/24/2019, 01:43 PM
Updated 05/24/2019, 01:56 PM
© Reuters. A Johnson & Johnson building is shown in Irvine, California

By Nate Raymond

(Reuters) - Gail Box vividly remembers the day in May 2011 when she first learned her 22-year-old son Austin, a University of Oklahoma linebacker, was abusing opioid painkillers: It was the day he died of an overdose.

In a few months he had gone from taking pills prescribed for a back injury to illicitly obtaining more of the addictive drugs from acquaintances.

"We did not know he was abusing," she said. "At that time, there was a lot of over-prescribing, and I think people in his life were able to get him opioids."

The question of why painkillers flooded into Oklahoma and the rest of the country will be the a central issue in a trial beginning Tuesday in Norman, Oklahoma, pitting the state against two drugmakers it accuses of fueling the epidemic: Johnson & Johnson (NYSE:JNJ) and Teva Pharmaceutical Industries (NYSE:TEVA) Ltd.

Oklahoma Attorney General Mike Hunter's $17 billion lawsuit is the first to go to trial of more than 2,000 actions by state and local governments accusing opioid manufacturers of contributing to an epidemic linked to a record 47,600 overdose deaths in 2017, according to the U.S. Centers for Disease Control and Prevention.

The state will seek to convince Cleveland County District Judge Thad Balkman to find that the companies created a public nuisance by using deceptive marking that downplayed their drugs' addictive risks while overstating their benefits. Balkman will rule following the trial, which will last eight weeks.

The state resolved related claims against OxyContin maker Purdue Pharma LP in March for $270 million.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

J&J and Teva deny wrongdoing, arguing the state lacks evidence linking any marketing they did to doctors writing unwarranted opioid prescriptions.

They also argue that even if they falsely marketed their products, the state cannot prove they caused the opioid epidemic given the role doctors, patients, pharmacists and drug dealers played in it.

"The FDA-approved labels for these prescription pain medications provide clear information about their risks and benefits," New Brunswick, New Jersey-based J&J said in a statement. "The allegations made against our company are baseless and unsubstantiated."

Israeli drugmaker Teva in a statement said it has in no way contributed to opioid abuse in Oklahoma and will vigorously defend itself.

In the wake of Purdue's March settlement with Oklahoma, the state dropped many of its claims against the other two defendants and shifted its focus primarily to J&J, which it claims "acted as the kingpin behind this public health emergency.

The state claims J&J and Teva deceptively marketed opioids with Purdue by retaining prominent doctors to give talks advocating use of opioids to treat chronic rather than short-term pain. It also says the companies funded groups that purported to be independent and these groups in turn promoted the misrepresentations.

The state claims J&J even marketed painkillers to children. It says the company, which formerly marketed the painkillers Duragesic and Nucynta, also grew and imported the raw materials to make the drugs.

MEMORIES OF TOBACCO SETTLEMENT

The Oklahoma case is being closely watched by plaintiffs in other opioid cases, particularly some 1,850 mostly municipal and state governments that have sued the same drugmakers in federal court in Ohio. The judge in that litigation is pushing the parties to reach a settlement agreement ahead of a scheduled October trial.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Some plaintiffs' lawyers have compared the opioid cases to litigation by states against the tobacco industry that led to a $246 billion settlement in 1998.

Paul Hanly, a lead lawyer for the plaintiffs in the Ohio litigation, said the Oklahoma trial could have major implications for a nationwide settlement.

"We will have an opportunity to see how these theories play out," he said. "Anyone who cares about public health issues should care about how the industry, or a portion of the industry, fares in this case."

Box said she believes "greed" in the pharmaceutical industry caused the epidemic. Box, whose husband, Craig, will testify, said she hopes any money the state recovers can be used to fund treatment and research to fight opioid addiction.

"Those are the things I'm hoping come out of this," she said. "Because at least myself and other families who lost loved ones, nothing is going bring them back."

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.